Vergoeding 2019-2023 voor ATC-subgroep J05AP : Antivirale middelen voor behandeling van hcv-infecties
- Raming voor de totale Zvw-populatie
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| J05AP01 Ribavirine | 75.357 | 37.694 | 12.925 | 8.866 | 1.140 |
| J05AP07 Daclatasvir | 11.424 | . | . | . | . |
| J05AP08 Sofosbuvir (Sovaldi ®) | 197.790 | 189.850 | 100.710 | 77.960 | 107.190 |
| J05AP51 Sofosbuvir met ledipasvir (Harvoni ®) | 1.090.200 | 279.400 | 151.400 | 112.070 | 50.136 |
| J05AP54 Elbasvir met grazoprevir (Zepatier ®) | 1.713.100 | 1.168.800 | 580.340 | 425.570 | 423.210 |
| J05AP55 Sofosbuvir met velpatasvir (Epclusa ®) | 5.040.800 | 2.119.800 | 1.793.500 | 2.134.800 | 1.574.300 |
| J05AP56 Sofosbuvir met velpatasvir en voxilaprevir (Vosevi ®) | 729.290 | 299.300 | 436.330 | 549.390 | 218.260 |
| J05AP57 Glecaprevir met pibrentasvir (Maviret ®) | 9.726.300 | 7.216.000 | 7.589.200 | 6.183.600 | 5.539.200 |
| Totaal | 18.584.261 | 11.310.844 | 10.664.405 | 9.492.256 | 7.913.436 |